Heart failure & cardiomyopathies
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
Primary result · Mean event-free survival, 55-year-old participantResult — go to the resultGain in event-free survival 3.1 years 95% CI 0.8–5.4Authors' conclusion
In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with finerenone was estimated to extend event-free survival by up to 3 years among people with HF with mildly reduced or preserved ejection fraction.
Study context
- Population
- Adults ≥40 years with symptomatic heart failure (HF) and LVEF ≥40%
- Participants
- 6,001 adults
- Comparison
- Finerenone vs placebo
- Primary endpoint
- Time to CV death or worsening HF event; long-term event-free survival gain estimated from age-based Kaplan-Meier curves
- Follow-up
- Median 2.6 years
Methodological detailsprespecified, phase 3, 653 sites in 37 countries
- Prespecified
- Phase 3
- 653 sites in 37 countries
Primary result
As reported in the abstract
Mean event-free survival, 55-year-old participant
Gain in event-free survival
3.1 years
95% CI 0.8–5.4
P = 0.007
By group
Further findings
Event-free survival, 65-year-old participant
gain (years) 2.0 (0.8–3.3) · P = 0.001
Projected event-free survival, starting ages 50 to 80 years
- Numerically greater with finerenone than placebo at every starting age
Lifetime event-free survival gain, already on SGLT2 inhibitor (subgroup), 65-year-old participant
- Gain in event-free survival 3.1 years (95% CI, 0.1-6.0 years)
- P = 0.04
Original publication
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. Published 1 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →